Clinical Trials Sponsored by I. Mechnikov Research Institute of Vaccines and Sera

Total 18 results

I.M. Sechenov First Moscow State Medical University
I. Mechnikov Research Institute of Vaccines and Sera

Completed

The Effect of Probiotics on Oral Health

Oral Disease

Russian Federation
St. Petersburg Research Institute of Vaccines and...

Active, not recruiting

Immunogenicity, Efficacy and Safety Trial of the Convacell Vaccine in Healthy Volunteers Aged 18 Years and Older

Coronavirus Infections | Respiratory Tract Infections | COVID-19 | COVID-19 Respiratory Infection

Russian Federation
St. Petersburg Research Institute of Vaccines and...

Completed

Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza Vaccine

Vaccine Reaction | Influenza | Influenza, Human | Vaccination; Infection | Influenza Viral Infections

Russian Federation
St. Petersburg Research Institute of Vaccines and...

Completed

Trial of Tolerability, Safety and Immunogenicity of the Flu-M Vaccine in Children Between 6 Months and 9 Years Old

Influenza, Human | Vaccination; Infection | Vaccines

Russian Federation
St. Petersburg Research Institute of Vaccines and...

Completed

Safety and Reactogenicity Trial of Vaccine for the Prevention of Infections Caused by Haemophilus Influenzae Type b

Vaccines | Haemophilus Influenzae Infection

Russian Federation
St. Petersburg Research Institute of Vaccines and...

Completed

The Objectives of This Study Are Comparative Assessment of the Tolerability, Safety and Immunogenicity of the Flu-M Vaccine vs. the Ultrix® Vaccine by Single Vaccination of Children Aged 6 to 17 Years.

Influenza

Russian Federation
St. Petersburg Research Institute of Vaccines and...

Completed

The Objectives of This Study Are Study of the Reactogenicity, Safety and Immunogenicity of Flu-M Inactivated Split Influenza Vaccine in Volunteers Aged 18-60 Years

Influenza

Russian Federation
St. Petersburg Research Institute of Vaccines and...

Completed

The Objectives of This Study Are Study the Safety, Reactogenicity and Obtain Preliminary Data on the Immunogenicity of Flu-M Quadro, 4-valent Inactivated Split Influenza Vaccine, in Healthy Volunteers

Influenza

Russian Federation
St. Petersburg Research Institute of Vaccines and...

Completed

The Objectives of This Study Are Study the Immunogenicity and Safety of the Flu-M [Inactivated Split Influenza Vaccine], vs. the Ultrix® Inactivated Split Influenza Vaccine, in Volunteers Who Are Over 60 Years Old

Influenza

Russian Federation
St. Petersburg Research Institute of Vaccines and...

Recruiting

Tolerability, Safety and Immunogenicity Trial of the Flu-M Tetra Vaccine in Children

Vaccine Reaction | Influenza | Influenza, Human | Influenza Viral Infections

Russian Federation
St. Petersburg Research Institute of Vaccines and...

Completed

Tolerability, Safety and Immunogenicity Trial of the FLU-M® Tetra

Influenza

Russian Federation
St. Petersburg Research Institute of Vaccines and...

Completed

Trial of Tolerability, Reactogenicity, Safety and Immunogenicity of Flu-M [Inactivated Split Influenza Vaccine] in Pregnant Women

Influenza, Human | Vaccination; Infection | Vaccines

Russian Federation
St. Petersburg Research Institute of Vaccines and...

Completed

Tolerability and Reactogenicity Trial of the Recombinant Tuberculosis Allergen in Healthy Volunteers

Tuberculosis | Skin Tests

Russian Federation
St. Petersburg Research Institute of Vaccines and...

Completed

Tolerability, Safety and Immunogenicity Trial of the Flu-M® Inactivated Vaccine in Volunteers Aged 18 to 60 Years

Influenza | Flu, Human

Russian Federation
St. Petersburg Research Institute of Vaccines and...

Completed

Trial of the Reactogenicity, Safety and Immunogenicity of the Flu-M Vaccine Manufactured by FSUE SPbSRIVS FMBA

Influenza

Russian Federation
St. Petersburg Research Institute of Vaccines and...
Crocus Medical B.V (The Netherlands)

Completed

Study of the Immunogenicity, Safety and Tolerability of the Convacell Vaccine.

Coronavirus Infections | Respiratory Tract Infections | COVID-19 | Immunologic Factors

Russian Federation
National Research Center - Institute of Immunology...
St. Petersburg Research Institute of Vaccines and Sera

Completed

The siCoV/KK46 Drug Open-safety Study

COVID-19

Russian Federation
National Research Center - Institute of Immunology...
St. Petersburg Research Institute of Vaccines and Sera

Completed

Evaluation of Safety & Efficacy of MIR 19 ® Inhalation Solution in Patients With Moderate COVID-19

COVID-19

Russian Federation

Clinical Trials Sponsored by I. Mechnikov Research Institute of Vaccines and Sera

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations